Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23664116 | 0.98 | ABL1 (0.59) | ABL1KCNH2 | |
| SCHEMBL15391653 | 0.92 | ABL1 (0.70) | ABL1KCNH2 | |
| SCHEMBL23664079 | 0.91 | ABL1 (0.70) | ABL1KCNH2 | |
| SCHEMBL19904278 | 0.91 | ABL1 (0.69) | ABL1KCNH2 | |
| SCHEMBL23664096 | 0.91 | ABL1 (0.71) | ABL1KCNH2 | |
| SCHEMBL19881056 | 0.90 | ABL1 (0.60) | ABL1KCNH2 | |
| SCHEMBL19904471 | 0.90 | ABL1 (0.60) | ABL1KCNH2 | |
| SCHEMBL23664091 | 0.89 | ABL1 (0.64) | ABL1 | |
| SCHEMBL21456915 | 0.89 | ABL1 (0.65) | ABL1KCNH2 | |
| SCHEMBL31391018 | 0.89 | ABL1 (0.65) | ABL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122928-A1 | SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE, AND PREPARATION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021213380-A1 | SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE, AND PREPARATION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021143927-A1 | COMPOUND ACTING AS BCR-ABL INHIBITOR | 正大天晴药业集团股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-2858988-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| EP-2861579-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017186148-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE BCR-ABL INHIBITORS | ASTAR BIOTECH LLC (US) | 2017-11-02 | — | — | WO | disclosed |